Wilson Sonsini Goodrich & Rosati has advised InduPro on the transaction. InduPro, Inc., a biotechnology company focused on developing novel therapeutics for cancer and autoimmune diseases,...
InduPro Secures $77 Million in Series B Financing for Oncology and Autoimmune Pipeline Advancement
Novartis to Acquire Excellergy in Potential $2 Billion Deal for Allergy Therapeutics
Wilson Sonsini Goodrich & Rosati has advised Excellergy on the transaction. Excellergy, a biotechnology company specializing in the development of novel allergy therapeutics, announced its planned...
Nosis Bio Expands Strategic Collaboration with Johnson & Johnson in Neurology
Wilson Sonsini Goodrich & Rosati has advised Nosis Bio. Nosis Bio, an AI-driven biopharmaceutical company specializing in cell-specific delivery for RNA medicines, has announced an expansion...
Azalea Therapeutics Secures $82 Million in Seed and Series A Financing for In Vivo Genomic Medicine Platform
Wilson Sonsini Goodrich & Rosati has advised Azalea Therapeutics on the transaction. Azalea Therapeutics, a biotechnology company specializing in precision genomic medicines delivered in vivo, has...
Callio Therapeutics’ $187 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Novo Holdings, Platanus, and Pureos Bioventure, as investors on the transaction. Callio Therapeutics, a biotechnology company focused on realizing the...
Cyrano Therapeutics’ Option Agreement with KYORIN
Wilson Sonsini Goodrich & Rosati advised Cyrano Therapeutics on the transaction. Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss,...
Circle Pharma’s Research Collaboration with Boehringer Ingelheim
Wilson Sonsini advised Circle Pharma on the transaction. Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class...
Pyxis Oncology’s Acquisition of Apexigen
Sidley Austin LLP advised Pyxis Oncology, Inc. on the transaction, while Wilson Sonsini advised Apexigen on the transaction. Pyxis Oncology, Inc., a clinical-stage company, and Apexigen,...
Denali Therapeutics’ $316 Million Public Offering
Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...